Monthly Archives: January 2008

The Regenerative Medicine Job Search: The Interview

Posted on January 30, 2008 by shsiong

by Susan Hsiong, PhD You’ve been submitting resumes like nobody’s business. And contacted everyone you know asking if they know of any job opportunities. You’ve attended all the local networking events and career fairs. After what seems like forever, you … Continue reading →

Posted in Job search, Regenerative Medicine | Tagged , , , | 7 Comments

Tengion Pioneers Autologous Tissue Engineered Regenerative Medicine Products

Posted on January 29, 2008 by jrowley

You have to hand it to Tengion, they are trying to tackle one of the largest challenges I can think of: producing tissue engineered organs and tissues from a patients own cells in unrelated indications (bladder, blood vessel, and kidney). … Continue reading →

Posted in autologous, Biomaterials, Bioprocessing, Clinical Trials, combination products, Company Profiles, JNJ, patient specific cell therapy, personalized medicine, Regenerative Medicine, Tengion, tissue engineered product, vascular regeneration | Tagged , , | 3 Comments

The Job Search: Large vs. Small Companies – pros and cons

Posted on January 25, 2008 by jrowley

Here is another take on working in a big company from ScienceMag (http://sciencecareers.sciencemag.org/career_development/tools_resources/forum/view?id=3845) Continue reading →

Posted in Job search, Regenerative Medicine | Tagged , , | 8 Comments

Pervasis Advances Tissue Engineered Products for Vascular Health

Posted on January 22, 2008 by jrowley

Pervasis Therapeutics announced that they have raised $9.75M to further develop their allogenic tissue engineered endothelial cell (EC) product for vascular health indications. Their Vascugel product is comprised of ECs grown in 3D collagen sponges that are implanted externally on … Continue reading →

Posted in Biomaterials, Bioprocessing, cell delivery, Clinical Trials, combination products, Company Profiles, Manufacturing, Pervasis, Regenerative Medicine, tissue engineered product, vascular regeneration | Tagged , , , , , | 1 Comment

Mimetic Solutions Pioneers New Smart Biomaterials for Controlled Release

Posted on January 18, 2008 by shsiong

When we have a cold or a headache, we pop a pill. We get sick, we go to the doctor and get a shot. Taking medication orally via a pill or getting drugs injected via a syringe are some of … Continue reading →

Posted in Biomaterials, biomimetics therapeutics, combination products, controlled release, diabetes, Mimetic Solutions, Regenerative Medicine, Smart materials | Tagged , , , , | Leave a comment

Osiris Scores $225M DoD Contract for Acute Radiation Syndrome Treatment with Prochymal Adult Stem Cell Product

Posted on January 12, 2008 by jrowley

Osiris Therapeutics announced that they won a DoD contract worth up to $224.7 million for developing their adult mesenchymal stem cell (MSC)-based therapeutic for treating acute radiation exposure. The contract allows for reimbursement of up to $24.7 million for continued … Continue reading →

Posted in adult stem cell, business models, Clinical Trials, DoD, MSCs, Osiris, Regenerative Medicine, stem cells | Tagged , , , , , | 1 Comment

China and the Regenerative Medicine Industry

Posted on January 11, 2008 by jrowley

Just a quick note on a topic that keeps catching my attention: China. Three interesting things have come up in the last month: Organogenesis signs a distribution deal with China’s National Tissue Engineering Center, with the potential to expand into … Continue reading →

Posted in Regenerative Medicine | 1 Comment

Consolidation Trends Within the Blossoming RegenMed Service Sector

Posted on January 9, 2008 by jrowley

The WuXi acquisition of Apptec (posted last week) is continuing the trend of consolidation in the cell manufacturing sector. It is similar to Lonza’s (a Swiss company) purchase of Cambrex’s biologics division in 2006, and GE’s purchase of Wave Biotech … Continue reading →

Posted in Apptec, BD, Bioprocessing, Invitrogen, JNJ, Lonza, Manufacturing, Progenitor Cell Therapy, Regenerative Medicine, Stem Cells Inc, WuXi Pharmatech | 1 Comment

Biomimetics Therapeutics Expands into New Markets with Innovative GEM OS Combination Device

Posted on January 8, 2008 by shsiong

by Susan Hsiong, PhD Biomimetics Therapeutics, Inc. (Franklin, TN), a company which develops drug-device combination products for orthopedic applications, recently announced positive results from its Canadian clinical study evaluating its GEM OS®1 Bone Graft for the open surgical treatment of … Continue reading →

Posted in Biomaterials, biomimetics therapeutics, bone regeneration, combination products, Company Profiles, controlled release, Medtronic, Regenerative Medicine | Tagged , , , , , , , , | 3 Comments

Chinese CRO WuXi Pharmatech Acquires Apptec Laboratory Services

Posted on January 7, 2008 by jrowley

WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to … Continue reading →

Posted in Apptec, BD, Bioprocessing, business models, Company Profiles, Invitrogen, JNJ, Lonza, Manufacturing, Regenerative Medicine, WuXi Pharmatech | 1 Comment

Celgene Strengthens Adult Stem Cell Patent Estate

Posted on January 4, 2008 by jrowley

I have recently signed up for the StemCellPatents.com weekly newsletter, and it is great to keep updated on all the patents that get issued in regenerative medicine. In the most recent newletter, they reported on two patents that issued last … Continue reading →

Posted in adult stem cell, Biomaterials, Celgene, Intellectual Property, placenta stem cells, Regenerative Medicine, stem cells | Tagged , , , , | 1 Comment

New Year’s Resolutions for the Regenerative Medicine Industry

Posted on January 2, 2008 by jrowley

With the New Year upon us, I thought it would be good to make a set of New Year’s Resolutions for the regenerative medicine industry. This set of resolutions is not company specific, but things that will be required to … Continue reading →

Posted in business models, Innovation, Regenerative Medicine | Tagged , , , | 2 Comments